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1. Introduction 
1.1 Epidemiology of social anxiety disorder (SAD) 
SAD, also known as social phobia, is characterised by excessive fear of embarrassment or 
humiliation in social situations, which in turn leads to marked distress or avoidance of these 
situations and functional impairment as described in DSM-IV-TR. 
It is a common disorder with early onset, significant comorbidity and functional impairment 
(Meron Ruscia et al., 2008).  
SAD has been ranked as one of the top ten chronic disorders – mental or physical – in terms 
of its effects on objective outcomes, such as days of work lost and reduced health-related 
quality of life (Alonso, 2004). According to the National Comorbidity Survey, SAD is the 
most reported anxiety disorder and has a lifetime prevalence of 12% (Kessler et al., 2005), 
with considerable coexisting psychiatric disorders, such as depression, anxiety, and 
substance-related disorders.Lifetime prevalence of social anxiety disorder  among Turkish 
university students was 23% (Dilbaz 2006). Co-occurring SAD and depression carry a 
substantial risk of suicide, which further complicates treatment (Beesdo et al., 2007; Thase, 
2007). SAD symptoms normally emerge during early adolescence and continue throughout 
adulthood; they affect women more often than men (Fehm et al., 2005).In clinical samples 
the ratio of male and female changes in the favour of males. (Dilbaz and Güz 2002). Trials 
suggest that social anxiety even below the diagnostic threshold is clearly associated with 
adverse outcomes like elevated risk for comorbid disorders and associated with impairment 
in diverse areas of life. 
Despite the growing understanding of this condition, information is lacking on key aspects 
of the disorder and many individuals, including doctors, psychiatrists and patients, 
unaware about this condition.  
1.2 Children and adolescents 
SAD, which so often begins in childhood, precedes other comorbid disorders and may be a 
direct or indirect risk factor for other disorders, such as depression and substance abuse. 
Epidemiologic findings show that in the pediatric primary healthcare setting anxiety 
disorders are very common ranging from 1% to 10% (Briggs-Gowan et al., 2000; Busch et al., 
2002; Costello, 1989), but are unrecognized and under-treated (Chavira et al., 2004; Wren et 
al., 2003). In community settings, rates of SAD in youth range from 0.5% to 4% (Essau et al., 
1999; Wittchen et al., 1998) and from 3% to 6.8% in primary care settings (Busch et al., 2002; 
Costello, 1989; Chavira et al., 2004). Recent research suggest that lifetime prevalence rates in 
adolescents in the US and Germany are between 5% and 15% (Heimberg et al., 2000; 
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Lewinsohn et al., 1993). Although the age of onset is usually in the early teens with a mean 
age of onset of 15.5 years (Schneider et al., 1993) children as young as 8 years old have been 
diagnosed with the disorder (Beidel & Turner, 1998). 
Shyness, behavioral inhibition and selective mutism can be considered in spectrum of social 
anxiety disorder in childhood. Children who are rated by their parents as having a shy 
temperament in infancy or in early childhood had an approximately 2 or 3 times increased 
probability of having an anxiety disorder in adolescence (Prior et al, 2000). In a five year 
longitudinal study, researchers found that behavioral inhibition-which can be described as a 
tendency to demonstrate fearfulness or resistance when faced with an unfamiliar stimuli, in 
pre-school children appeared to be a predictor for social anxiety in middle school 
(Hirshfeld-Becker et al., 2007). Selective mutism can be considered an extreme form of social 
anxiety including features of shyness and behavioral inhibition, where the most prominent 
feature is the inhibition of speech in select situations. Comorbidity rates between selective 
mutism and social anxiety disorder range from 70–95% (Dummit et al., 1997; Black & Uhde, 
1995) and characteristics such as shyness, anxiousness, withdrawal and seriousness are used 
to describe both selective mutism and social anxiety alike (Steinhausen & Juzi, 1996; 
Kumpulainen et al., 1998). 
Studies have shown that in children aged 7–13 years with SAD, 60% had an additional 
psychiatric diagnosis, of whom 36% had an anxiety disorder as follows: generalized anxiety 
disorder 10%; attention deficit hyperactivity disorder 10%; specific phobia 10%; and 
selective mutism 8% (Biedel et al., 1999). Those individuals who develop comorbid 
disorders will also have an increased risk of suicidal ideation and suicide attempts. 
In treatment of social anxiety disorders in childhood and adolecence, most practitioners 
advise the initial use of psychological interventions followed by pharmacotherapy when 
necessary. Specific treatments have employed cognitive-behavioral group therapy for SAD 
in adolescents, social effectiveness therapy for children (Beidel et al., 2000) and ‘coping cat’ 
child behavior therapy (Flannery-Schroeder et al., 2000). Overall, most clinical researchers 
now believe that CBT is the treatment of choice for youth with internalizing disorders 
including SAD (March et al., 2003). 
There are very few pharmacotherapy trials in general and even fewer randomized, double-
blind, placebo-controlled trials in childhood anxiety disorders. Studies with both open-label 
and double blind placebo control groups have shown promising results ranging from 36–
100% success rates (Compton et al., 2001; Mancini et al., 1999). Selective serotonin reuptake 
inhibitors (SSRI) and serotonin norepinephrine reuptake inhibitors (SNRI) are defined as 
first line pharmacotherapy for social anxiety disorders in youth with a careful assessessment 
of suicidal ideation before starting these antidepressants. 
The development of comorbid mental disorders such as depression and substance abuse, 
children and adolescents with this illness are at risk for educational or occupational under-
achievement, and failure to achieve financial and emotional independence. The challenge of 
preventing the consequences of SAD lies in early diagnosis. 
2. Organic etiology of SAD 
Although the etiology of SAD is poorly understood, emerging evidence indicates 
multidimensional causes. It is a distinct psychiatric disorder with genetic underpinnings 
and is associated with neurobiological and environmental mechanisms.  
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Over the past two decades, numerous neurobiological methods have been used in studies of 
SAD including structural, functional and receptor brain imaging, pharmacological trials, 
candidate gene investigations and studies of psychophysiological, endocrine, biochemical 
and behavioral responses to stressful challenges. It has been hypothesized that affect 
regulation is compromised in individuals with SAD, either due to hyperactivity in emotion 
triggering areas like the amygdala and insula, or hypoactivity in modulatory regions like the 
anterior cingulate and prefrontal cortices. It also has been hypothesized that SAD patients 
would show exaggerated amygdala responses to angry or threatening faces in comparison 
to healthy control subjects and that amygdala hyperresponsivity is associated with 
enhanced fear conditionability in SAD (Furmark, 2009).  
A range of neurotransmitters may be important in SAD including the monoamines, 
glutamate, GABA, and several neuropeptides, but to date, the serotonergic and 
dopaminergic transmission systems have received most of the attention. 
Serotonin has been implicated in animal models of fear and anxiety (Graeff, 2002) and the 
therapeutic efficacy of SSRIs (Ipser et al., 2008) strongly suggests that serotonin has a crucial 
role in SAD.  Allelic variation in serotonin-related genes modulate amygdala responsivity both 
in healthy volunteers (Hariri & Holmes, 2006) and in patients with SAD (Furmark et al., 2004). 
Lanzenberger et al. demonstrated a significantly lower serotonin-1A receptor binding potential 
in SAD patients relative to controls in the amygdala, anterior cingulate cortex, insula, and 
dorsal raphe nuclei in their PET study (Lanzenberger et al., 2007). Serotonergic involvement is 
also supported by neuroendocrine challenges studies (Tancer, 1993). 
Dopamine is known to play a central role in motivation and reward-seeking behaviors and 
several lines of evidence point to a dysfunction of this transmitter system in SAD like 
patients with Parkinson’s Disease, which is associated with dopamine hypofunction, appear 
to have enhanced risk for developing SAD (Richard et al., 1996). Abnormal central 
dopaminergic neurotransmission has also been reported in animal trials relevant to SAD, 
such as studies of social subordination in primates (Grant et al., 1998). Two independent 
SPECT studies also point directly to an altered dopamine system activity in SAD. Tiihonen 
et al. reported that the striatal dopamine reuptake site density was markedly lower in 
patients with SAD than controls, presumably reflecting a smaller number of dopaminergic 
synapses and neurons in the basal ganglia (Tiihonen et al., 1997). Schneier et al. also 
observed that striatal dopamine D2 receptor binding was significantly lower in subjects with 
SAD than in comparison subjects (Schneier et al., 2000). 
Genetically-oriented studies of SAD and related constructs such as behavioral inhibition, 
neuroticism, introversion and harm-avoidance suggest that genetic factors play at least a 
moderate role in the etiology of excessive social anxiety (Stein et al., 1994). The short (s) 
allele of the promoter polymorphism of the human serotonin transporter gene (the 5-HTT-
linked polymorphic region; 5-HTTLPR) has been associated with anxiety-related personality 
traits, increased fear conditionability, and life-stress-induced aff ective disorder (Serretti et 
al., 2006). Several other genotypes influence amygdala responsivity and could thus be 
considered in future studies of SAD, for example the tryptophan hydroxylase-2 gene (G-
703T polymorphism) (Brown et al., 2005) and the catechol-Omethyltransferase gene (COMT 
Val158Met) (Smolka et al., 2005). 
3. Diagnosis and assessment of SAD 
The first challenge in the treatment of SAD is making a correct diagnosis. There is evidence 
that SAD is under-diagnosed and under-treated in primary care and specialist settings alike 
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(Katzelnick & Greist, 2001). Possible reasons for this may be lack of diagnostic awareness, 
lack of diagnostic threshold clarity or the presence of co-morbid disorders. Moreover, as 
consultation with a clinician may be perceived as social interaction, the nature of the 
disorder may cause patients to delay seeking help, and when they eventually do, it is often 
with physical complaints or psychiatric comorbidity. 
During the initial evaluation it is important to find out severity of symptoms as well as the 
degree of avoidance and functional impairment present. Rating scales such as the Liebowitz 
social anxiety scale that is translated and validated to Turkish also, may be helpful in 
assessing both feared situations and avoidance and can be used to monitor the patient’s 
treatment progress (Liebowitz 1987, Dilbaz and Guz ). A range of other SAD scales are also 
available, like the Brief Social Phobia Scale (clinician rated) and the Social Phobia Inventory 
(patient rated) (Davidson et al., 1997; Conner et al., 2000). 
4. Co-morbidity 
Significant comorbidity of social anxiety and mood disorders have been consistently shown 
in the literature (Kessler et al., 1999; Lecrubier & Weiller, 1997; Pini et al. 1997). Social 
anxiety has also been linked to severity (Merikangas & Angst, 1995) and persistence (Alpert 
et al. 1997) of mood disorders. Also comorbid mood disorders have worsen social anxiety 
symptoms and result in greater impairment in patients with SAD (Erwin et al., 2002). A 
significant number of patients presenting with social anxiety will have a secondary anxiety 
disorder, particularly panic disorder with agoraphobia and generalized anxiety disorder 
(Mennin et al. 2000, Schneier et al., 1992).  Comorbid depressive or anxiety disorders 
complicate SAD, the severity of symptoms and suicidality should be assessed and 
hospitalisation considered if indicated. In such cases, the treatment of choice should ideally 
target both the mood and the anxiety components.  
Social phobia and avoidant personality disorder were introduced in the DSM 
classification system nearly 30 years ago. Since then it has been shown that these two 
disorders can be found highly comorbid in patients, in some trials as high as 89% 
(Schneier et al., 1991). Some researchers have interpreted this high rate of overlap to mean 
that social phobia and avoidant personality disorder reflect a spectrum of social anxiety 
(Tillfors & Ekselius, 2009).  
Social anxiety disorder is associated with high rates of alcohol use disorders (Morris et al., 
2005). Almost half of the patients with lifetime SAD meet criteria for lifetime prevalence of an 
alcohol use disorder (Grant et al.,2005) and it is a significantly high rate when compared to 
general population. Among the anxiety disorders, SAD shows a particularly problematic risk 
profile for comorbid alcohol use disorders, as SAD is associated with higher rates of alcohol 
use disorders relative to most other anxiety disorders (Kessler et al.,1997).  
Recently, researchers have identified that individuals with SAD appear particularly 
vulnerable to marijuana-related problems too. Data from the National Comorbidity Study 
suggest that individuals with SAD are 7 times more likely to experience marijuana 
dependence relative to the general population (Agosti et al, 2002) and undergraduates with 
higher social anxiety appear to be particularly vulnerable to marijuana use problems 
(Buckner et al, 2007; Buckner et al., 2008a). In a study, adolescents with SAD were nearly 5 
times more likely to develop marijuana dependence as young adults compared to 
adolescents without SAD (Buckner et al., 2008b). 
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5. Treatment of SAD 
Current recommended treatment options for social anxiety disorder include 
pharmacotherapy and cognitive behavioural therapy (CBT). (Dilbaz 2005) Although several 
randomised controlled trials (RCTs) have failed to show efficacy for β-adrenoceptor 
antagonists in generalised SAD, it has been suggested that these agents may be useful in 
non-generalised SAD, patients with performance anxiety only. Efficacy in the treatment of 
generalised SAD has been demonstrated for a number of interventions, (Stein, 2003; Blanco 
et al., 2003) including SSRIs, high potency benzodiazepines (e.g. clonazepam), MAOIs (e.g. 
phenelzine), reversible inhibitors of monoamine oxidase A (MAO-A) [RIMAs, e.g. 
moclobemide], certain antiepileptics (e.g. gabapentin, pregabalin), serotonin-noradrenaline 
reuptake inhibitors (venlafaxine) and CBT (Zaider & Heimberg 2003).  
5.1 Nonpharmacological treatments 
These treatments include exposure, cognitive re-structuring, relaxation techniques and 
social skills training, often used in combination.  Literature have concluded that cognitive 
behavioral therapy (CBT) is often effective for treating social anxiety disorder. The goal of 
cognitive behavioral therapy (CBT) is to provide techniques and practice to patients with 
social anxiety disorder, so they can learn to change how they think about and behave in 
situations that terrify them. CBT may be offered individually or as part of group therapy. 
There is continued interest in the question of whether group or individual treatment is more 
effective. Early studies suggested some superiority for group treatment (Wlazlo et al., 1990), 
and arguments were raised that the group setting would provide a richness of exposure 
experiences not easily replicated in individual treatment; by the late 1990s the weight of 
evidence suggested that there was no clear superiority between group and individual 
treatment (Gould et al., 1997). 
Meta-analyses of the efficacy of CBT for SAD that have compared various types of CBT with 
each other and with control conditions have yielded the highest effect sizes for exposure-
based interventions (Federof & Taylor, 2001; Hope et al.,1995). In exposure therapy, the type 
of CBT most often used and studied for social anxiety disorder, therapists gradually expose 
patients to the dreaded situation and suggest ways to manage fear. The exposure-based 
extinction of fear is now thought to involve new learning that actively inhibits the fear 
reaction to a given cue (Davis et al., 2006). In other variations of CBT— not as well studied 
as exposure therapy— patients learn and practice social skills and relaxation techniques. 
5.2 Pharmacological treatments 
SSRIs; evidence from RCTs supports that the efficacy and tolerability of almost all SSRIs 
(escitalopram (Stein et al.,2005), fluvoxamine, (Van Vliet et al.,1994; Stein et al., 1999) 
paroxetine, (Liebowitz et al., 2002; Baldwin et al., 1999; Stein et al., 1998) sertraline 
(Katzelnicket al., 1995; Liebowitz et al., 2003), fluoxetin (Black et al., 1992), citalopram 
(Bouwer & Stein, 1998) in the treatment of SAD, so SSRIs can be regarded as first-line 
treatment in SAD. These agents have the additional benefit of treating comorbid conditions 
commonly seen with SAD (Van Ameringen et al., 2004). Fluoxetine, fluvoxamine and 
sertraline have been the most studied SSRIs in socially phobic children and adolescents and 
have shown good efficacy and tolerability in this group (Robinson & Hood, 2007). 
Venlafaxine; has shown promising results in open-label and controlled trials in the 
treatment of SAD. Venlafaxine is an effective treatment option for generalised social anxiety 
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disorder but has no superiority from paroxetine in clinical trials (Allgulander et al., 2004; 
Liebowitz et al., 2005). While venlafaxine is an effective treatment, this may be related to its 
serotonergic profile, and the authors are unimpressed with response to the specific 
noradrenergic agent reboxetine from both the literature and clinical experience. Venlafaxine 
is associated with significant side effects and discontinuation syndrome and described as 
second-line treatments of social anxiety in most settings (Robinson & Hood, 2007). 
MAOIs; Phenelzine was one of the first established treatments for SAD with several early 
double-blind, placebo-controlled trials demonstrating efficacy in this disorder (Versiani et 
al., 1992; Gelernter et al., 1991). In light of their adverse effect profiles and the dietary 
restrictions associated with use of these agents, together with the availability of alternative 
treatments, MAOIs are currently not considered to be a first-line treatment for SAD. 
RIMAs; reversible inhibitors of monoamine oxidase A, appears inferior to that of phenelzine 
in efficacy but the main advantages of moclobemide over phenelzine are superior 
tolerability and no concern about dietary restrictions at the standart dosage of 600 mg/day 
moclobemide. This may be a particularly important consideration in the long-term 
treatment of SAD (Stein et al., 2002). 
Benzodizepines, despite the positive results, the adverse effect profile, the potential for 
dependence, the possibility of rebound anxiety, the possible negative consequences of state-
dependent learning and their ineffectiveness in the treatment of depression shows that these 
agents should not be considered as first-line monotherapy for SAD (Jackson 1995; Keith et 
al., 2003). 
Beta Blockers; Beta-blockers are effective at blocking peripheral autonomic symptoms such 
as tachycardia, tremor, sweating, blushing and dry mouth and thus have a potential role as 
anxiolytics. They are effectively used in the treatment of performance anxiety but there is 
substantial evidence that beta-blockers are not effective in social phobia (Liebowitz et al., 
1992; Turner et al., 1994) and that better options are available. A limited role in performance 
anxiety is indicated. 
Gabapentine, Pregabalin and Levetirasetam; Some anticonvulsants trials suggest that 
gabapentin, pregabalin and levetirasetam could be alternative agents for patients who are 
nonresponsive to SSRIs and SNRIs (Pande et al., 1999; Pande et al., 2004; Zhang et al., 2005). 
However these agents need further studies about the safety and efficacy in SAD. 
Other pharmacological agents for treatment of SAD; Tricyclic antidepressants have been 
used but failed to be an effective treatment choice for social anxiety disorder (Emmanuel 
et al., 1997; Simpson et al., 1998). There are trials with buspirone in literature but these 
trials have both negative and positive outcomes in social anxiety disorder. So that 
buspirone may be a useful agent for augmentation in social anxiety disorder (Robinson & 
Hood, 2007 ). There is a little evidence for bupropion efficacy in social phobia (Emmanuel 
et al., 2000). There are trials that have found mirtazapine as an effective treatment option 
for social anxiety disorder (Mrakotsky et al., 2007; Mörtberg, 2006). However in a recent 
study mirtazapine showed  no superiority to placebo for treatment of SAD (Shutters et al., 
2010).  
Atypical antipsychotics have been shown to have anxioloytic properties in the literature 
(Depping et al., 2010; Vulink et al., 2011). Olanzapine (Barnett et al., 2002) and quetiapine 
(Vaishavi et al., 2007) have been found effective as monotherapy in the treatment of SAD. In 
another study switchover to aripiprazole effectively improved social anxiety in patiets with 
schizophrenia (Stern et al., 2009). 
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5.3 Inadequate response to pharmacotherapy and augmentation strategies  
Criteria for remission of SAD proposed by Ballenger (Ballenger, 2001) include absence of 
core symptoms of  SAD, no or minimal anxiety (e.g. in anticipation of social interaction) as 
rated by rating scales such as the Hamilton Rating Scale for Anxiety, no functional 
impairment (the Sheehan Disability Scale may be used to evaluate this), (Sheehan et al., 
1996) and remission of course of action when first-line treatment with a co-morbid 
depression as reflected by the Hamilton Rating Scale for Depression. It should, however, be 
noted that the mean reduction in Liebowitz Social Anxiety Scale scores was <50% in a 
review of 19 double-blind, placebo-controlled trials involving patients with SAD. Switching 
to another SSRIs, venlafaxine or MAOIs has been suggested in non responders or patients 
with adverse event. Augmentation strategies that may prove useful in partial treatment 
responders include buspirone, clonazepam, gabapentin, bupropion or new generation 
antipsychotics, although empirical data are lacking (Barnett et al., 2002; Schutters et al., 2005; 
Pallanti et al., 1999). 
In case of comorbidity moclobemide was found to be effective and well-tolerated in the SAD 
patients with anxiety disorders as well as SSRIs. In the presence of co-morbid alcohol abuse, 
MAOIs and benzodiazepines can complicate the treatment, SSRIs have usefulness in 
reducing the alcohol consumption (Naranjo & Knoke, 2001). CBT may be the treatment of 
choice during pregnancy and lactation.  
6. Conclusion 
SAD is a prevalent and disabling disorder that often remains undetected unless the 
clinicaian takes a careful history. Present consensus supports that SSRIs can currently be 
regarded as first-line treatment in SAD because of their proven efficacy, tolerability and 
bility to treat co-morbid conditions such as depression or other anxiety disorders (Stein, 
2003; Blanco et al., 2003; Ballenger et al., 1998). There is a recent evidence venlafaxine XR 
may also be considered in the first-line. Second-line treatments include MAOIs (e.g. 
phenelzine) and RIMAs (e.g.moclobemide).  
The combination of CBT and an SSRI is often espoused as best practice, unfortunately there 
is little hard evidence supporting this (despite considerable face validity). Future studies 
taking a good look at combination therapies of this type are encouraged and also future 
research should focus on complicated and treatment refractory SAD and treatment 
strategies in special populations (e.g.children and adolescents). 
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